Home > Investors
Investor Relations Home
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Webcast ImageWebcast - Replay
Q3 2014 The Medicines Company Earnings Conference Call
10/22/14 at 8:30 a.m. ET
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$21.94
Change (%) Stock is Down 0.05 (0.23%)
Volume558,374
Data as of 10/24/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
10/24/14The Medicines Company Announces Participation in 2014 American College of Emergency Physicians Scientific Assembly
-Company’s Participation in the InnovatED Program to Highlight ABSSSI Clinical Innovation, as well as Management of Acute Severe Hypertension -Presentations Include Now Available ORBACTIV™ (oritavancin) and CLEVIPREX (clevidipine) PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 24, 2014-- The Medicines Company (NASDAQ:MDCO) will be represented at the American College of Emergency Physicians (ACEP) Annual Scientific Assembly in Chicago, which b... 
Printer Friendly Version
10/22/14The Medicines Company Reports Third Quarter and First Nine Months 2014 Results
Nine Month Net Revenues Rise 6% year over year Company Reports Progress with Product Candidates PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 22, 2014-- The Medicines Company (NASDAQ:MDCO), a global biopharmaceutical company focused on saving lives, alleviating suffering, and contributing to the economics of healthcare by focusing on the world's leading acute/intensive care hospitals, today announced third quarter and first nine month result... 
Printer Friendly Version
10/09/14ORBACTIV(TM) (Oritavancin) Phase 3 SOLO II Trial Results Published in the Journal Clinical Infectious Diseases
SOLO II Trial studied single-dose ORBACTIVTM (oritavancin) in the treatment of acute bacterial skin and skin structure infections caused by designated Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 9, 2014-- The Medicines Company (NASDAQ:MDCO) today announced the publication of the results from the SOLO II Phase 3 clinical trial of ORBACTIV (oritavanci... 
Printer Friendly Version
10/08/14The Medicines Company to Announce Third Quarter 2014 Financial Results on Wednesday, October 22, 2014
Conference Call to be held at 8:30 a.m. Eastern Time PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 8, 2014-- The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for Wednesday, October 22 at 8:30 a.m. Eastern Time to discuss third quarter financial results, guidance and operational developments. The conference call will be available via phone and webcast. The dial-in information is listed below: Dome... 
Printer Friendly Version
Upcoming Events
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.